Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 13/20 | 0.42 |
| ▸ | CTSD | P07339 | 9/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.33 |
| ▸ | REN | P00797 | 1/20 | 0.33 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285187 | 0.94 | BACE1 (0.40) | BACE1CTSDBACE2RENCYP2D6 | |
| SCHEMBL2282031 | 0.92 | BACE1 (0.39) | BACE1CTSDBACE2RENCYP2D6 | |
| SCHEMBL2279435 | 0.91 | BACE1 (0.42) | BACE1CTSDBACE2RENCYP11B1 | |
| SCHEMBL2286475 | 0.89 | BACE1 (0.41) | BACE1CTSDBACE2CYP17A1CYP11B1 | |
| SCHEMBL2286947 | 0.88 | BACE1 (0.42) | BACE1CTSD | |
| SCHEMBL2284435 | 0.86 | CTSD (0.48) | BACE1CTSD | |
| SCHEMBL2281408 | 0.86 | BACE1 (0.37) | BACE1CTSDBACE2REN | |
| Formic Acid SCHEMBL2278980 | 0.84 | BACE1 (0.56) | BACE1CTSDBACE2RENKCNH2 | |
| SCHEMBL2284061 | 0.84 | BACE1 (0.42) | BACE1CTSDBACE2RENCYP2D6 | |
| SCHEMBL2279615 | 0.83 | BACE1 (0.61) | BACE1CTSDKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245019-B1 | 4, 5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-11-14 | — | — | EP | disclosed |
| US-7989449-B2 | 4,5-dihydro-oxazol-2-yl amine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | BACE2, BACE1, PSEN2 | BACE1 2/4885CTSD 721/4885BACE2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.